These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7060036)

  • 41. [Acute and chronic renal failure in patients with myeloma].
    Biriukova LS; Volodiaeva EB; Fetisova EV; Pivnik AV; Margolin OV
    Ter Arkh; 1999; 71(7):58-64. PubMed ID: 10481869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.
    Carlson K
    Bone Marrow Transplant; 2005 May; 35(10):985-90. PubMed ID: 15806125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).
    Joffe JK; Bell JB; Denham S; Adshead F; Millar JL; Millar BC
    Exp Hematol; 1995 Apr; 23(4):376-82. PubMed ID: 7534716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toxicology and Carcinogenesis Studies of C.I. Pigment Red 3 (CAS No. 2425-85-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1992 Mar; 407():1-289. PubMed ID: 12621523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Melphalan in multiple myeloma.
    Hoogstraten B; Sheehe PR; Cuttner J; Cooper T; Kyle RA; Oberfield RA; Townsend SR; Harley JB; Hayes DM; Costa G; Holland JF
    Blood; 1967 Jul; 30(1):74-83. PubMed ID: 6028709
    [No Abstract]   [Full Text] [Related]  

  • 50. NTP Toxicology and Carcinogenesis Studies of 1,4-Dichlorobenzene (CAS No. 106-46-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Jan; 319():1-198. PubMed ID: 12748734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog.
    Page RL; Macy DW; Thrall DE; Dewhirst MW; Allen SL; Heidner GL; Sim DA; McGee ML; Gillette EL
    Cancer Res; 1988 Jan; 48(2):288-90. PubMed ID: 3335006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.
    Pineda-Roman M; Tricot G
    Contrib Nephrol; 2007; 153():182-94. PubMed ID: 17075230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermittent melphalan therapy in multiple myeloma.
    Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
    JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
    [No Abstract]   [Full Text] [Related]  

  • 54. Breast cancer and acute leukemia in a patient with multiple myeloma treated with melphalan.
    Meytes D; Katz DR
    Isr J Med Sci; 1973 Aug; 9(8):1044-7. PubMed ID: 4753846
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
    Alberts DS; Chen HG; Benz D; Mason NL
    Br J Cancer; 1981 Mar; 43(3):330-4. PubMed ID: 7225283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alkeran and multiple myeloma.
    Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
    [No Abstract]   [Full Text] [Related]  

  • 57. Light chain myeloma with features of the adult Fanconi syndrome: six years remission following one course of melphalan.
    von Schéele C
    Acta Med Scand; 1976; 199(6):533-7. PubMed ID: 820162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure.
    Pecherstorfer M; Zimmer-Roth I; Weidinger S; Irsigler K; Halbmayer WM; Ulrich W; Fischer M; Baumgartner G
    Clin Investig; 1994 Jul; 72(7):522-5. PubMed ID: 7981581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Intermittent melphalan-predniso(lo)ne massive-dose therapy of plasmacytoma].
    Braun HJ
    Dtsch Med Wochenschr; 1972 Jan; 97(3):84-6. PubMed ID: 5007398
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.